X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.
Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Valneva
Deal Size: $39.9 million Upfront Cash: $35.5 million
Deal Type: Termination September 16, 2022
Details:
A coronavirus vaccine, MVA-SARS-2-S vaccine, developed by the German Centre for Infection Research (DZIF) and vaccine maker IDT Biologika did not prompt the hoped-for immune reaction in early-stage testing on humans.
Lead Product(s): MVA-SARS-2-S vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: German Center for Infection Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.
Lead Product(s): MVA-SARS-2-S vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
